Cargando…

Tailoring of Retinyl Palmitate-Based Ethosomal Hydrogel as a Novel Nanoplatform for Acne Vulgaris Management: Fabrication, Optimization, and Clinical Evaluation Employing a Split-Face Comparative Study

AIM: Retinyl palmitate (RP), the most stable vitamin A derivative, is used to treat photoaging and other skin disorders. The need to minimize the adverse effects of topical drug administration has led to an enhanced interest in loading RP on ethosomes for topical drug delivery. The aim of the curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Salem, Heba F, Kharshoum, Rasha M, Awad, Sara M, Ahmed Mostafa, Mai, Abou-Taleb, Heba A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239256/
https://www.ncbi.nlm.nih.gov/pubmed/34211271
http://dx.doi.org/10.2147/IJN.S301597
_version_ 1783715040851918848
author Salem, Heba F
Kharshoum, Rasha M
Awad, Sara M
Ahmed Mostafa, Mai
Abou-Taleb, Heba A
author_facet Salem, Heba F
Kharshoum, Rasha M
Awad, Sara M
Ahmed Mostafa, Mai
Abou-Taleb, Heba A
author_sort Salem, Heba F
collection PubMed
description AIM: Retinyl palmitate (RP), the most stable vitamin A derivative, is used to treat photoaging and other skin disorders. The need to minimize the adverse effects of topical drug administration has led to an enhanced interest in loading RP on ethosomes for topical drug delivery. The aim of the current study was to prepare and compare the performance of RP decorated ethosomal hydrogel with tretinoin cream in the treatment of acne vulgaris as an approach to improve drug efficacy and decrease its side effects. METHODS: RP-loaded ethosomes were prepared using the injection sonication technique. A Box–Behnken design using Design Expert(®) software was used for the optimization of formulation variables. Particle size, zeta potential (ZP), entrapment efficiency percent (EE%), % drug release, and permeation over 24 h of different formulations were determined. The optimal formulation was incorporated into a hydrogel. Finally, the efficacy and tolerability of the optimized RP ethosomal hydrogel were clinically evaluated for acne treatment using a split-face comparative clinical study. RESULTS: The optimized ethosomal RP showed particle size of 195.8±5.45 nm, ZP of −62.1±2.85 mV, EE% of 92.63±4.33%, drug release % of 96.63±6.81%, and drug permeation % of 85.98 ±4.79%. Both the optimized RP ethosomal hydrogel and tretinoin effectively reduced all types of acne lesions (inflammatory, non-inflammatory, and total lesions). However, RP resulted in significantly lower non-inflammatory and total acne lesion count than the marketed tretinoin formulation. Besides, RP-loaded ethosomes showed significantly improved tolerability compared to marketed tretinoin with no or minimal skin irritation symptoms. CONCLUSION: RP ethosomal hydrogel is considerably effective in controlling acne vulgaris with excellent skin tolerability. Therefore, it represents an interesting alternative to conventional marketed tretinoin formulation for topical acne treatment.
format Online
Article
Text
id pubmed-8239256
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82392562021-06-30 Tailoring of Retinyl Palmitate-Based Ethosomal Hydrogel as a Novel Nanoplatform for Acne Vulgaris Management: Fabrication, Optimization, and Clinical Evaluation Employing a Split-Face Comparative Study Salem, Heba F Kharshoum, Rasha M Awad, Sara M Ahmed Mostafa, Mai Abou-Taleb, Heba A Int J Nanomedicine Original Research AIM: Retinyl palmitate (RP), the most stable vitamin A derivative, is used to treat photoaging and other skin disorders. The need to minimize the adverse effects of topical drug administration has led to an enhanced interest in loading RP on ethosomes for topical drug delivery. The aim of the current study was to prepare and compare the performance of RP decorated ethosomal hydrogel with tretinoin cream in the treatment of acne vulgaris as an approach to improve drug efficacy and decrease its side effects. METHODS: RP-loaded ethosomes were prepared using the injection sonication technique. A Box–Behnken design using Design Expert(®) software was used for the optimization of formulation variables. Particle size, zeta potential (ZP), entrapment efficiency percent (EE%), % drug release, and permeation over 24 h of different formulations were determined. The optimal formulation was incorporated into a hydrogel. Finally, the efficacy and tolerability of the optimized RP ethosomal hydrogel were clinically evaluated for acne treatment using a split-face comparative clinical study. RESULTS: The optimized ethosomal RP showed particle size of 195.8±5.45 nm, ZP of −62.1±2.85 mV, EE% of 92.63±4.33%, drug release % of 96.63±6.81%, and drug permeation % of 85.98 ±4.79%. Both the optimized RP ethosomal hydrogel and tretinoin effectively reduced all types of acne lesions (inflammatory, non-inflammatory, and total lesions). However, RP resulted in significantly lower non-inflammatory and total acne lesion count than the marketed tretinoin formulation. Besides, RP-loaded ethosomes showed significantly improved tolerability compared to marketed tretinoin with no or minimal skin irritation symptoms. CONCLUSION: RP ethosomal hydrogel is considerably effective in controlling acne vulgaris with excellent skin tolerability. Therefore, it represents an interesting alternative to conventional marketed tretinoin formulation for topical acne treatment. Dove 2021-06-24 /pmc/articles/PMC8239256/ /pubmed/34211271 http://dx.doi.org/10.2147/IJN.S301597 Text en © 2021 Salem et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Salem, Heba F
Kharshoum, Rasha M
Awad, Sara M
Ahmed Mostafa, Mai
Abou-Taleb, Heba A
Tailoring of Retinyl Palmitate-Based Ethosomal Hydrogel as a Novel Nanoplatform for Acne Vulgaris Management: Fabrication, Optimization, and Clinical Evaluation Employing a Split-Face Comparative Study
title Tailoring of Retinyl Palmitate-Based Ethosomal Hydrogel as a Novel Nanoplatform for Acne Vulgaris Management: Fabrication, Optimization, and Clinical Evaluation Employing a Split-Face Comparative Study
title_full Tailoring of Retinyl Palmitate-Based Ethosomal Hydrogel as a Novel Nanoplatform for Acne Vulgaris Management: Fabrication, Optimization, and Clinical Evaluation Employing a Split-Face Comparative Study
title_fullStr Tailoring of Retinyl Palmitate-Based Ethosomal Hydrogel as a Novel Nanoplatform for Acne Vulgaris Management: Fabrication, Optimization, and Clinical Evaluation Employing a Split-Face Comparative Study
title_full_unstemmed Tailoring of Retinyl Palmitate-Based Ethosomal Hydrogel as a Novel Nanoplatform for Acne Vulgaris Management: Fabrication, Optimization, and Clinical Evaluation Employing a Split-Face Comparative Study
title_short Tailoring of Retinyl Palmitate-Based Ethosomal Hydrogel as a Novel Nanoplatform for Acne Vulgaris Management: Fabrication, Optimization, and Clinical Evaluation Employing a Split-Face Comparative Study
title_sort tailoring of retinyl palmitate-based ethosomal hydrogel as a novel nanoplatform for acne vulgaris management: fabrication, optimization, and clinical evaluation employing a split-face comparative study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239256/
https://www.ncbi.nlm.nih.gov/pubmed/34211271
http://dx.doi.org/10.2147/IJN.S301597
work_keys_str_mv AT salemhebaf tailoringofretinylpalmitatebasedethosomalhydrogelasanovelnanoplatformforacnevulgarismanagementfabricationoptimizationandclinicalevaluationemployingasplitfacecomparativestudy
AT kharshoumrasham tailoringofretinylpalmitatebasedethosomalhydrogelasanovelnanoplatformforacnevulgarismanagementfabricationoptimizationandclinicalevaluationemployingasplitfacecomparativestudy
AT awadsaram tailoringofretinylpalmitatebasedethosomalhydrogelasanovelnanoplatformforacnevulgarismanagementfabricationoptimizationandclinicalevaluationemployingasplitfacecomparativestudy
AT ahmedmostafamai tailoringofretinylpalmitatebasedethosomalhydrogelasanovelnanoplatformforacnevulgarismanagementfabricationoptimizationandclinicalevaluationemployingasplitfacecomparativestudy
AT aboutalebhebaa tailoringofretinylpalmitatebasedethosomalhydrogelasanovelnanoplatformforacnevulgarismanagementfabricationoptimizationandclinicalevaluationemployingasplitfacecomparativestudy